Clinical evaluation of elderly patients with sarcopenia receiving Shenling baizhu powder combined with nutrition and exercise intervention

JIANG Huanhuan; CHEN Dong; FU Aishuang; GE Yanlei; WANG Qiang; LI Shizi; SHEN Huiqin; LI Xia; WANG Yingcong; CHEN Yunfei

doi:10.6039/j.issn.1001-0408.2024.21.13

您当前的位置：

首页 >

文章列表页 >

Clinical evaluation of elderly patients with sarcopenia receiving Shenling baizhu powder combined with nutrition and exercise intervention

更新时间：2024-11-08

- Clinical evaluation of elderly patients with sarcopenia receiving Shenling baizhu powder combined with nutrition and exercise intervention
- ZHONGGUO YAOFANG Vol. 35, Issue 21, Pages: 2652-2657(2024)
- 作者机构：
  
  1.华北理工大学附属医院药学部，河北唐山　063000
  2.华北理工大学附属医院临床营养科，河北唐山　063000
  3.华北理工大学附属医院呼吸内科，河北唐山　063000
  4.河北北方学院附属第二医院药剂科，河北张家口　075000
  5.河北北方学院附属第二医院临床营养科，河北张家口　075000
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.21.13
  CLC： R969;R956
- Published：15 November 2024，
  
  Received：06 February 2024，
  
  Revised：23 October 2024，
- 稿件说明：
移动端阅览
蒋欢欢,陈冬,付爱双等.老年肌少症患者接受参苓白术散联合营养支持和运动干预的临床评价 ^Δ[J].中国药房,2024,35(21):2652-2657.

JIANG Huanhuan,CHEN Dong,FU Aishuang,et al.Clinical evaluation of elderly patients with sarcopenia receiving Shenling baizhu powder combined with nutrition and exercise intervention[J].ZHONGGUO YAOFANG,2024,35(21):2652-2657.
蒋欢欢,陈冬,付爱双等.老年肌少症患者接受参苓白术散联合营养支持和运动干预的临床评价 ^Δ[J].中国药房,2024,35(21):2652-2657. DOI： 10.6039/j.issn.1001-0408.2024.21.13.

JIANG Huanhuan,CHEN Dong,FU Aishuang,et al.Clinical evaluation of elderly patients with sarcopenia receiving Shenling baizhu powder combined with nutrition and exercise intervention[J].ZHONGGUO YAOFANG,2024,35(21):2652-2657. DOI： 10.6039/j.issn.1001-0408.2024.21.13.

摘要

目的

探讨老年肌少症患者接受参苓白术散联合营养支持和运动干预的安全性、有效性和经济性，为临床合理用药提供参考。

方法

将237例老年肌少症患者随机分为观察组（118例）和对照组（119例）。2组患者均给予营养支持和运动干预；观察组患者在此基础上加用参苓白术散，每次6 g，每天3次；3个月后比较2种方案的安全性、有效性和经济性。

结果

2组患者均顺利完成随访。干预前，2组患者的骨骼肌质量指数（SMI）、握力和6 m步速比较，差异均无统计学意义（

＞0.05）。干预后，观察组患者的握力显著大于对照组（25.05 kg vs. 23.18 kg，

＜0.01）；肌少症治疗有效率、SMI和6 m步速虽高于或大于对照组，但差异均无统计学意义（

＞0.05）。观察组患者的不良反应/事件发生率虽低于对照组（14.41% vs.

16.81%），但差异无统计学意义（

＝0.611）。与对照组方案相比，观察组方案的成本较高（981.25元 vs. 913.94元）、效果较好（有效率0.618 6 vs. 0.563 0），增量-成本效果比为1 210.61元。敏感性分析结果与成本-效果分析结果一致。

结论

老年肌少症患者接受参苓白术散联合营养支持和运动干预后，可显著增强握力，且不会提高不良反应/事件的发生率；与对照组方案相比较，观察组每增加1例肌少症治疗有效患者需多花费1 210.61元。

Abstract

OBJECTIVE

To explore the safety， effectiveness， and cost-effectiveness of elderly patients with sarcopenia receiving Shenling baizhu powder combined with nutrition and exercise intervention， providing a reference for rational clinical drug use.

METHODS

A total of 237 elderly sarcopenia patients were randomly assigned to an observation group （118 cases） and a control group （119 cases）. Both groups of patients received nutrition and exercise intervention； the observation group added Shenling baizhu powder （6 g each time， three times daily） on this basis. The safety， effectiveness， and cost-effectiveness of the two plans were compared after 3 months.

RESULTS

Both groups of patients completed the follow-up. Before intervention， no significant diffe

rence was observed in skeletal muscle index （SMI）， grip strength， and 6-minute walk test （6MWT） speed between the two groups （

＞0.05）. After intervention， the grip strength of the patients in the observation group was significantly greater than that of the control group （25.05 kg vs. 23.18 kg，

＜0.01）； the treatment response rate of sarcopenia， SMI， and 6MWT speed were higher than those of the control group， but the differences were not statistically significant （

＞0.05）. The adverse reaction/event rate of the patients in the observation group was lower than that of the control group （14.41% vs. 16.81%，

＝0.611）， but the difference was not statistically significant. Compared with the control group’s plan， the cost of the observation group’s plan was higher （981.25 yuan vs. 913.94 yuan）， and the effect was better （effectiveness rate： 0.618 6 vs. 0.563 0）， with an incremental cost-effectiveness ratio of 1 210.61 yuan. The results of the sensitivity analysis were consistent with the cost-effectiveness analysis results.

CONCLUSION

Elderly patients with sarcopenia who receive Shenling baizhu powder combined with nutrition and exercise intervention can significantly strengthen grip strength without increasing the incidence of adverse reactions/events. Compared with the control group plan， the observation group needs to spend an additional 1 210.61 yuan for each additional effective patient with sarcopenia.

关键词

参苓白术散老年肌少症营养支持运动干预成本-效果分析

Keywords

elderlysarcopenianutrition supportexercise interventioncost-effectiveness analysis

references

蒋欢欢，陈冬，申慧琴，等. 老年肌少症患者实施营养运动干预的效果评价[J]. 现代预防医学，2023，50（18）：3383-3388，3401.

JIANG H H，CHEN D，SHEN H Q，et al. Effectiveness evaluation of nutrition sports treatment for sarcopenia in elderly[J]. Mod Prev Med，2023，50（18）：3383-3388，3401.

蒋欢欢，申慧琴，王志秀，等. 参苓白术散治疗老年男性肌少症的成本-效用分析[J]. 药物流行病学杂志，2023，32（4）：376-383.

JIANG H H，SHEN H Q，WANG Z X，et al. Cost-utility analysis of Shenling baizhu powder in treatment of sarcopenia in older men[J]. Chin J Pharmacoepidemiol，2023，32（4）：376-383.

崔华，王朝晖，吴剑卿，等. 老年人肌少症防控干预中国专家共识：2023[J]. 中华老年医学杂志，2023，42（2）：144-153.

CUI H，WANG C H，WU J Q，et al. Chinese expert consensus on prevention and intervention for elderly with sarcopenia：2023[J]. Chin J Geriatr，2023，42（2）：144-153.

郑筱萸. 中药新药临床研究指导原则：试行[M]. 北京：中国医药科技出版社，2002：361-377.

ZHENG X Y. Guiding principles for clinical research of traditional Chinese medicine new drugs：trial implementation[M]. Beijing：China Medical Science and Technology Press，2002：361-377.

CHEN L K，WOO J，ASSANTACHAI P，et al. Asian Working Group For Sarcopenia：2019 consensus update on sarcopenia diagnosis and treatment[J]. J Am Med Dir Assoc，2020，21（3）：300-307.e2.

吴芸杨，陈晓宏，季晶俊，等. 肌肉衰减综合征的诊断和治疗进展[J]. 医学综述，2020，26（22）：4499-4503.

WU Y Y，CHEN X H，JI J J，et al. Research progress of diagnosis and treatment of sarcopenia[J]. Med Recapitul，2020，26（22）：4499-4503.

河北省医疗保障局. 河北省药品集中采购平台[EB/OL]. [2023-08-22]. http：//ylbzj.Hebei.gov.cnhttp://ylbzj.Hebei.gov.cn.

Hebei Medical Security Bureau. Hebei province drug centralized procurement platform[EB/OL]. [2023-08-22]. http：//ylbzj.Hebei.gov.cnhttp://ylbzj.Hebei.gov.cn.

河北省统计局.河北省2022年国民经济和社会发展统计公报[R/OL].（2023-02-25）[2023-10-05].http：//tjj.hebei.gov.cn/hetj/app/tjgb/101672190375289.htmlhttp://tjj.hebei.gov.cn/hetj/app/tjgb/101672190375289.html.

Hebei Provincial Bureau of Statistics. Statistical bulletin on national economic and social development of Hebei Province in 2022[R/OL].（2023-02-25）[2023-10-05]. http：//tjj.hebei.gov.cn/hetj/app/tjgb/101672190375289.htmlhttp://tjj.hebei.gov.cn/hetj/app/tjgb/101672190375289.html.

谭重庆，彭六保，曾小慧，等. 药物经济学评价中敏感度分析的参数分布[J]. 中国新药与临床杂志，2015，34（12）：961-964.

TAN C Q，PENG L B，ZENG X H，et al. Distributions for parameters in sensitivity analysis of pharmacoeconomics evaluation[J]. Chin J New Drugs Clin Remedies，2015，34（12）：961-964.

王琴，张彬，林萍，等. 参苓白术散治疗肌少症患者的临床疗效观察[J]. 中华危重病急救医学，2021，33（8）：994-998.

WANG Q，ZHANG B，LIN P，et al. Clinical effect of Shenling baizhu san on patients with sarcopenia[J]. Chin Crit Care Med，2021，33（8）：994-998.

胡飞，赵晓光. 体育运动与营养补剂对老年性骨骼肌减少症的干预[J]. 中国老年学杂志，2023，43（6）：1524-1530.

HU F，ZHAO X G. Intervention of physical exercise and nutritional supplements on senile skeletal muscle deficiency[J]. Chin J Gerontol，2023，43（6）：1524-1530.

薛新宏，王晓光，陶徉聿，等. 营养联合运动干预对脑卒中伴肌少症患者的效果[J]. 中国康复理论与实践，2023，29（5）：595-600.

XUE X H，WANG X G，TAO Y Y，et al. Effect of nutrition combined with exercise on stroke patients with sarcopenia[J]. Chin J Rehabil Theory Pract，2023，29（5）：595-600.

裴泽华，蔡轶男，王乐兵，等. 肌少症现状及蛋白质对其预防作用的研究进展[J]. 食品工业科技，2022，43（24）：469-477.

PEI Z H，CAI Y N，WANG L B，et al. Research progress of current situation of sarcopenia and the preventive effect of protein on it[J]. Sci Technol Food Ind，2022，43（24）：469-477.

BANERJEE A，MAROTTA F，SRIRAMULU S，et al. Beyond physical exercise：the role of nutrition，gut microbiota and nutraceutical supplementation in reducing age-related sarcopenia[J]. Curr Aging Sci，2021，14（2）：94-104.

POZIOS I，KAUFMANN D，BOUBARIS K，et al. Impact of myopenia and myosteatosis on postoperative outcome and recurrence in Crohn’s disease[J]. Int J Colorectal Dis，2022，37（4）：791-804.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Cost-effectiveness analysis of apatinib combined with adriamycin for second-line treatment of platinum-resistant recurrent ovarian cancer

Cost-effectiveness analysis of tislelizumab combined with chemotherapy as first-line treatment for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma

Cost-effectiveness analysis of serplulimab combined with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma

胸腺五肽联合TP方案治疗晚期非小细胞肺癌的成本-效果分析

丹参川芎嗪注射液联合厄贝沙坦治疗糖尿病肾病的成本-效果分析

Related Author

CHEN Xia

ZHOU Jiaqi

LIU Xiaoya

ZHAN Shaoqing

LIU Guoqiang

NIU Mengna

GUO Shan

GAO Shengnan

Related Institution

Dept. of Pharmacy， Nantong First People’s Hospital

Dept. of Clinical Pharmacy， Hebei Medical University Third Hospital

Hebei Society for Integrated Drug and Health Technology Assessment

School of International Pharmaceutical Business， China Pharmaceutical University

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰